advertisement

Cancer

03 June 2010

Vaccine against deadly brain cancer shows promise

A small, early-stage trial of a therapeutic brain cancer vaccine developed by ImmunoCellular Therapeutics Ltd showed that nearly half the patients were alive without their cancer worsening 18 months after diagnosis, the company said on Wednesday

0

This article has not necessarily been edited by Health24.

LOS ANGELES (Reuters) - A small, early-stage trial of a therapeutic brain cancer vaccine developed by ImmunoCellular Therapeutics Ltd showed that nearly half the patients were alive without their cancer worsening 18 months after diagnosis, the company said on Wednesday. The Phase 1 trial involved 16 patients with glioblastoma multiforme, the most common and deadly form of brain cancer. They were treated with ICT-107, an experimental dendritic cell based cancer vaccine, following the standard care of surgery, radiation and chemotherapy."We are targeting specific antigens that are on cancer stem cells ... the only population of cells that can really propagate a tumor," said Dr. John Yu, director of surgical neuro-oncology at Cedars-Sinai Medical Center in Los Angeles and ImmunoCellular's chief scientific officer.A year after diagnosis, all of the patients were alive. After two years, 80% were alive.Historically, after a year with standard treatment, 61% of glioblastoma patients are alive, and 26.5% are alive after two years, according to the company.In the ImmunoCellular trial, median overall survival had not yet been reached at the 26.4 months analysis point, with 12 out of 16 patients alive. Seven patients continued to live with no disease progression.Side effects seen in the trial included fatigue and skin rash.Dr. Yu said ImmunCellular is planning a mid-stage trial of the vaccine that would include between 30 and 50 patients.

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst. For more information, visit cansa.org.za.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules